# BPC-157 TB-500 Dosage in Research: Reported Ranges, Routes, Half-Life

> BPC-157 TB-500 dosage as reported in preclinical studies: component animal-model ranges, routes of administration, reconstitution, and the absence of any validated blend dose or human protocol.

Component-level animal-study doses, routes, and half-lives — and why no validated blend dose exists. Research context, not a human protocol.

## BPC-157 and TB-500 Dosage Ranges Reported in Preclinical Studies

There is no validated dose for the BPC-157 TB-500 blend. Commercial research-product labeling commonly pairs the two at fixed combined masses per vial (for example ~10 mg BPC-157 + ~10 mg TB-500, or a 20 mg combined vial), but no peer-reviewed combination dose-finding study exists [6]. Every figure below is a dose administered to animals in a specific study, reported as such — not guidance for human use.

For the BPC-157 component, rodent studies commonly express dose per body weight, frequently around 10 μg/kg and 10 ng/kg; the transected-Achilles result used those ranges intraperitoneally [1], and gastric-ulcer cytoprotection has been studied at 400-800 ng/kg in rats. For the TB-500 / Thymosin Beta-4 component, the range is wide: a rat embolic-stroke dose-response study spanned 2-18 mg/kg intraperitoneally, with an optimal modeled around 3.75 mg/kg and 18 mg/kg giving no benefit — higher was not better [4]. An mdx muscular-dystrophy study used 150 μg twice weekly intraperitoneally for six months [4].

The honest summary: the constituents have animal-model dose records; the blend does not. Anyone presenting a fixed-ratio vial as a validated dose is presenting community practice, not controlled-trial evidence [6].

## What is the half-life of BPC-157 and TB-500?

No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study. Human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but no specific half-life is established for the TB-500 heptapeptide [4].

### What is the half-life of BPC-157 and TB-500?
No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study. Human IV full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide [4]. See [half-life and reconstitution](/dosage#reconstitution) below.

### How do you cycle BPC-157 and TB-500?
No validated human cycling protocol appears in the literature. Community "loading then maintenance" blend schedules have no controlled-trial basis, and a rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic — 18 mg/kg gave no benefit — which undercuts "more is better" loading rationales [4]. The underlying animal studies use widely differing schedules by species and route.

### How often should you inject BPC-157 and TB-500?
The literature records no validated human injection frequency for the blend. The underlying animal studies use widely differing schedules — for example Thymosin Beta-4 at 150 μg twice weekly intraperitoneally for six months in one mouse study [4] — and community frequency protocols have no controlled-trial basis. Findings should be described as "studied at X in [species]," not framed as human schedules.

## Routes of Administration Reported in the Component Literature

The wolverine injection question — how the blend is administered — has only a research-context answer. In the underlying rodent efficacy studies for both peptides, the predominant route was intraperitoneal [1][4]. Subcutaneous and intramuscular routes predominate in research-community practice but not in controlled human efficacy trials. Intravenous administration appears in human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 safety pilot. Local, intra-lesional, and topical routes appear in individual-compound wound and tendon models.

None of these is a human-use instruction. They describe how the molecules were delivered in the studies that generated the findings.

### How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Commercial vials are commonly labeled with a combined per-vial mass (e.g. 10 mg + 10 mg), but product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. No human-use reconstitution instructions apply to a research chemical.

## Oral vs. Parenteral Administration in Reviewed Preclinical Models

The "bpc 157 tb 500 oral" question turns on a real difference between the two peptides. BPC-157 is studied in the literature as a "stable gastric" peptide, with peroral administration appearing in some rodent models. TB-500 / Thymosin Beta-4 work is overwhelmingly parenteral. Either way, no validated oral pharmacokinetics exist for the blend, and oral blend products that are marketed lack a controlled PK basis [6].

Reconstitution and handling are practical questions with research-only answers: lyophilized powder, bacteriostatic or sterile water, refrigeration. The identity caveat around TB-500 — fragment versus full-length Thymosin Beta-4 — compounds in unregulated material, where the actual ratio is unverified [4][5]. See [the combination research](/combination-research) for why that doubled uncertainty matters.

## The only human reference points are for the full-length parent

It is worth being precise about what "human dose" data exist, because the blend has none of its own. The human single-agent reference points in the record are for full-length Thymosin Beta-4, not the TB-500 heptapeptide and not the blend: intravenous Thymosin Beta-4 has been reported as well tolerated in early-phase safety work, with dose-proportional pharmacokinetics [4]. BPC-157's human exposure is limited to three small pilot studies — a two-person intravenous safety pilot, an intra-articular knee-pain case series, and a 12-patient intravesical interstitial-cystitis pilot — none of which establishes a dose for the assembled blend [6].

The reviewer's bottom line on dosage is unglamorous and firm. The constituents have animal-model dose records and, for the full-length parent of one of them, a little human safety data. The Wolverine blend has neither a validated dose nor a validated human pharmacokinetic profile, and a fixed-ratio vial is a commercial convention, not a finding [6]. Treat any single number presented as "the dose" with the skepticism a missing study deserves.

---

The BPC-157 TB-500 record played back like a two-sided release — each peptide read against its own studies on its own side, the combination track left silent because no controlled trial recorded it, and the FDA 503A status printed in the liner notes; no clinic pressed it and nothing here is for sale.